Research Roundup

Debbie Rigby takes a look at the latest in research news Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes Evaluation Of patients in the ORBIT-AF II trial shows 541 NOAC-treated patients (9.4%) were underdosed, 197 were overdosed (3.4%), and 5,000 were dosed according to U.S. labeling (87%). NOAC overdosing was associated with